DermTech, Inc.

DermTech, Inc. (Nasdaq: DMTK) is a molecular diagnostics company focused on non-invasive genomic skin analysis, operating in the dermatology and precision medicine sector. The company went public in 2019 through a business combination with Constellation Alpha Capital Corp, a SPAC sponsored by Constellation Alpha Capital LLC. DermTech's flagship platform uses adhesive patch technology to collect skin cells for genomic testing, targeting early melanoma detection. The company's June 2024 Form 8-K filing reflects a period of significant operational and financial transition following years of commercialization challenges in the clinical genomics space. For full filing details, financial data, and SPAC deal history on DMTK, sign up for complete access at SpacDesk.